Company: SCLXW
Filing Date: 2025-08-21
Form Type: 424B3
Source: 0001193125-25-184627
Chunk: 15

Company: Scilex Holding Co
Filing Date: 2025-08-21
Form: 424B3
Chunk 15
---
 and has assumed all of the duties formerly performed by Jaisim Shah. Jaisim Shah will continue to serve on the Board of Directors of Scilex. Jaisim Shah will now dedicate his time on a full-time basis to his continued service as Chief Executive Officer and President of Semnur. In 2013, Mr. Shah co-foundedSemnur, and he has served as its CEO and President through the acquisition of Semnur by Scilex in 2019 and continues to serve in this position as of today. Page | 1

As previously announced, Semnur and Denali are parties to a pending business combination (the
“Business Combination”), which is expected to close in September 2025. “As Semnur is in the process of becoming a public company through its business combination with Denali, having a fully dedicated CEO is an important milestone
and would serve to unlock Semnur’s potential value. Our team and I are proud to continue our leadership in the creation of prescription non-opioid therapeutics addressing
non-opioid pain management for the millions of acute and chronic pain patients,” said Jaisim Shah, Chief Executive Officer and President of Semnur. “Semnur looks to accelerate its mission to
increase access to prescription non-opioid therapeutics by further advancing its lead product, SP-102, through the final phase of clinical development for the treatment
of LRP/sciatica. We are grateful to all of our investors and partners for supporting us through our successful transition.”

Henry Ji, Ph.D.,
Scilex’s Chairman and newly appointed Chief Executive Officer and President, stated, “Jaisim has played a prominent role in Scilex’s rapid commercial growth and product development. We credit him with many important strategic
contributions, particularly in regards to: Scilex’s acquisition of Semnur in 2019; the launch of ZTlido and making ZTlido the number one prescribed branded non-opioid analgesic by pain specialists, with 1 million patients treated since its launch in 2018; in-licensing and launch of ELYXYB and Gloperba; and contributions to the completion of the first SP-102 Phase 3 clinical trial. We
are very appreciative of Jaisim for his work and commitment to Scilex, and we know he will bring tremendous value and leadership skills to Semnur as it is advancing the second Phase 3 clinical